2/27
07:41 am
ibrx
ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026 [Yahoo! Finance]
Low
Report
ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026 [Yahoo! Finance]
2/27
07:30 am
ibrx
ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026
Low
Report
ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026
2/26
07:49 pm
ibrx
Assessing ImmunityBio (IBRX) Valuation After Trial Progress And Strong Anktiva Commercial Momentum [Yahoo! Finance]
Low
Report
Assessing ImmunityBio (IBRX) Valuation After Trial Progress And Strong Anktiva Commercial Momentum [Yahoo! Finance]
2/26
11:35 am
ibrx
Is It Too Late To Consider ImmunityBio (IBRX) After The Recent Share Price Surge? [Yahoo! Finance]
Low
Report
Is It Too Late To Consider ImmunityBio (IBRX) After The Recent Share Price Surge? [Yahoo! Finance]
2/26
10:16 am
ibrx
SHINE Raises $240 Million in Funding to Advance Commercial Fusion Technology [Yahoo! Finance]
Medium
Report
SHINE Raises $240 Million in Funding to Advance Commercial Fusion Technology [Yahoo! Finance]
2/26
07:38 am
ibrx
ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ [Yahoo! Finance]
Low
Report
ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ [Yahoo! Finance]
2/26
07:30 am
ibrx
ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
Low
Report
ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
2/26
05:32 am
ibrx
SHINE Completes $240 Million in Recent Funding Led by Dr. Patrick Soon-Shiong, Founder of NantWorks, Who Joins Board of Directors [Yahoo! Finance]
Low
Report
SHINE Completes $240 Million in Recent Funding Led by Dr. Patrick Soon-Shiong, Founder of NantWorks, Who Joins Board of Directors [Yahoo! Finance]
2/26
02:35 am
ibrx
ImmunityBio (IBRX) Loses 17% to Profit-Taking After Intra-Day High [Yahoo! Finance]
Low
Report
ImmunityBio (IBRX) Loses 17% to Profit-Taking After Intra-Day High [Yahoo! Finance]
2/25
04:42 pm
ibrx
ImmunityBio (IBRX) Skyrockets as Anktiva Propels 671% Revenue Jump [Yahoo! Finance]
Low
Report
ImmunityBio (IBRX) Skyrockets as Anktiva Propels 671% Revenue Jump [Yahoo! Finance]
2/25
07:26 am
ibrx
ImmunityBio: Disconnect Between Clinical Progress And Stock Performance [Seeking Alpha]
High
Report
ImmunityBio: Disconnect Between Clinical Progress And Stock Performance [Seeking Alpha]
2/25
06:22 am
ibrx
ImmunityBio (IBRX) Reports 700% Revenue Surge Driven by Rapid ANKTIVA Adoption [Yahoo! Finance]
High
Report
ImmunityBio (IBRX) Reports 700% Revenue Surge Driven by Rapid ANKTIVA Adoption [Yahoo! Finance]
2/24
01:41 pm
ibrx
ImmunityBio's ANKTIVA Approvals Broaden Global Reach And Investor Opportunity [Yahoo! Finance]
Low
Report
ImmunityBio's ANKTIVA Approvals Broaden Global Reach And Investor Opportunity [Yahoo! Finance]
2/23
04:15 pm
ibrx
ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit
High
Report
ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit
2/23
03:05 pm
ibrx
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Low
Report
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
2/23
01:05 pm
ibrx
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
2/23
12:42 pm
ibrx
ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates [Yahoo! Finance]
Low
Report
ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates [Yahoo! Finance]
2/23
09:55 am
ibrx
ImmunityBio: Q4 Earnings Snapshot [Yahoo! Finance]
Medium
Report
ImmunityBio: Q4 Earnings Snapshot [Yahoo! Finance]
2/23
08:37 am
ibrx
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $23.00 price target on the stock.
Medium
Report
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $23.00 price target on the stock.
2/23
08:26 am
ibrx
ImmunityBio GAAP EPS of -$0.06, revenue of $38.2M [Seeking Alpha]
Medium
Report
ImmunityBio GAAP EPS of -$0.06, revenue of $38.2M [Seeking Alpha]
2/23
07:00 am
ibrx
ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally
High
Report
ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally
2/20
08:30 am
ibrx
ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients
Low
Report
ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients
2/19
08:06 pm
ibrx
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
2/19
09:00 am
ibrx
ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch
Medium
Report
ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch
2/19
08:02 am
ibrx
ImmunityBio (IBRX) Is Up 29.0% After EU Clears First ANKTIVA+BCG Immunotherapy For NMIBC CIS [Yahoo! Finance]
Low
Report
ImmunityBio (IBRX) Is Up 29.0% After EU Clears First ANKTIVA+BCG Immunotherapy For NMIBC CIS [Yahoo! Finance]